DexCom (DXCM) CEO on medical leave as board appoints interim leadership team

Rhea-AI Filing Summary

DexCom, Inc. announced that its Chief Executive Officer and Chairman, Kevin R. Sayer, has taken a temporary medical leave of absence effective September 14, 2025. To ensure continuity, the Board appointed Jacob S. Leach, the company’s President and Chief Operating Officer, to serve as interim principal executive officer while retaining his current responsibilities.

The Board also named Mark Foletta, the Lead Independent Director, as interim chairman of the Board. Neither Mr. Leach nor Mr. Foletta will receive additional compensation for these interim roles. The company states there is no special arrangement under which Mr. Leach was selected, no family relationships between him and other directors or executives, and no related-party transactions involving him that require disclosure.

Positive

• None.

Negative

• Temporary medical leave of CEO and Chairman: Kevin R. Sayer’s leave introduces leadership uncertainty, even though existing senior executives have been appointed to interim roles.

Insights

Corporate governance and leadership transition analyst

DexCom discloses a temporary CEO medical leave with internal interim leadership appointments.

The company reports that CEO and Chairman Kevin R. Sayer has taken a temporary medical leave effective September 14, 2025. In response, the Board appointed President and COO Jacob S. Leach as interim principal executive officer and Lead Independent Director Mark Foletta as interim chairman. Both appointments keep leadership within existing senior ranks, which can help maintain operational continuity.

The filing clarifies that Messrs. Leach and Foletta will not receive additional compensation for these interim responsibilities and that there are no special selection arrangements, family relationships, or disclosable related-party transactions involving Mr. Leach. For investors, this is a leadership change driven by medical reasons, with the company emphasizing a temporary status and using established insiders to fill the key roles. The longer-term impact depends on the duration of the leave and any future updates the company may provide in subsequent disclosures.

8-K Event Classification

Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers

1 item

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

Understanding 8-K Material Events →

false000109355700010935572025-09-142025-09-14

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): September 14, 2025

DEXCOM, INC.

(Exact Name of the Registrant as Specified in Its Charter)

Delaware			000-51222			33-0857544
(State or Other Jurisdiction of Incorporation)			(Commission File Number)			(I.R.S. Employer Identification No.)

6340 Sequence Drive, San Diego, CA						92121
(Address of Principal Executive Offices)						(Zip Code)

(858) 200-0200

(Registrant’s Telephone Number, Including Area Code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class

Trading Symbol(s)

Name of Each Exchange on Which Registered

Common Stock, $0.001 Par Value Per Share

DXCM

Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

☐

ITEM 5.02.    DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS.

Effective September 14, 2025, Kevin R. Sayer, Chief Executive Officer (principal executive officer) and Chairman of the Board of DexCom, Inc. (“Dexcom” or the “Company”) is taking a temporary medical leave of absence.

Accordingly, effective September 14, 2025, Dexcom’s Board of Directors (the “Board”) appointed Jacob S. Leach, President and Chief Operating Officer, to serve as Dexcom’s interim principal executive officer, in addition to his current duties. In addition, Mark Foletta, Lead Independent Director of the Board, was appointed to serve as Dexcom’s interim chairman of the Board. Messrs. Leach and Foletta will not receive any additional compensation in connection with their respective interim appointments.

Biographical and other information for Mr. Leach is set forth in Dexcom’s definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission on March 27, 2025 and is incorporated herein by reference. There is no arrangement or understanding between Mr. Leach and any other persons pursuant to which he was selected as an officer. There are no family relationships among any of Dexcom’s directors or executive officers and Mr. Leach, and Mr. Leach does not have any direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

DEXCOM, INC.
By:						/s/ JEREME M. SYLVAIN Jereme M. Sylvain Executive Vice President, Chief Financial Officer
Date:						September 15, 2025

FAQ

What leadership change did DexCom (DXCM) disclose in this 8-K?

The company disclosed that Kevin R. Sayer, its Chief Executive Officer and Chairman of the Board, has taken a temporary medical leave of absence effective September 14, 2025.

Who is serving as DexCom’s interim principal executive officer?

Jacob S. Leach, DexCom’s President and Chief Operating Officer, has been appointed to serve as the company’s interim principal executive officer while continuing in his existing roles.

Who was appointed interim chairman of the board at DexCom (DXCM)?

Mark Foletta, the Board’s Lead Independent Director, was appointed to serve as DexCom’s interim chairman of the Board effective September 14, 2025.

Will DexCom’s interim leaders receive additional compensation for their new roles?

No. The filing states that Messrs. Leach and Foletta will not receive any additional compensation in connection with their respective interim appointments.

Are there any special arrangements or family relationships related to Jacob S. Leach’s appointment?

The company states there is no arrangement or understanding under which Mr. Leach was selected, no family relationships between him and any directors or executive officers, and no material related-party transactions requiring disclosure.

Where can investors find more background on Jacob S. Leach of DexCom?

Biographical and other information for Mr. Leach is included in DexCom’s definitive proxy statement on Schedule 14A filed on March 27, 2025, which is incorporated by reference.